Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma

Ibrutinib has previously been shown to inhibit Bruton’s tyrosine kinase (BTK) and interleukin-2–inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell maligna...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: Kumar, Anita, Vardhana, Santosha, Moskowitz, Alison J., Porcu, Pierluigi, Dogan, Ahmet, Dubovsky, Jason A., Matasar, Matthew J., Zhang, Zhigang, Younes, Anas, Horwitz, Steven M.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2018
Fag:
Lymphoid Neoplasia
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915998/
https://ncbi.nlm.nih.gov/pubmed/29669753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017011916
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker